LWCFA
PCRX icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Pacira BioSciences PCRX Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400
Closed -$9.56K – 551
2025
Q2 		$9.56K Hold
400
– – ﹤0.01% 483
2025
Q1 		$10.1K Hold
400
– – ﹤0.01% 483
2024
Q4 		$10.3K Hold
400
– – ﹤0.01% 488
2024
Q3 		$6.81K Hold
400
– – ﹤0.01% 512
2024
Q2 		$8.55K Hold
400
– – ﹤0.01% 498
2024
Q1 		$10.4K Hold
400
– – ﹤0.01% 492
2023
Q4 		$13K Sell
400
-20,600
-98% -$603K ﹤0.01% 486
2023
Q3 		$613K Sell
21,000
-1,000
-5% -$36K 0.01% 180
2023
Q2 		$882K Sell
22,000
-8,948
-29% -$370K 0.01% 158
2023
Q1 		$1.26M Sell
30,948
-4,782
-13% -$190K 0.01% 140
2022
Q4 		$1.38M Sell
35,730
-15,534
-30% -$756K 0.02% 133
2022
Q3 		$2.73M Sell
51,264
-178
-0.3% -$9.9K 0.04% 100
2022
Q2 		$3M Buy
51,442
+7,532
+17% +$493K 0.04% 100
2022
Q1 		$3.35M Buy
43,910
+2
+0% +$133 0.03% 103
2021
Q4 		$2.64M Buy
43,908
+8,295
+23% +$457K 0.02% 112
2021
Q3 		$1.99M Buy
35,613
+15,086
+73% +$869K 0.02% 123
2021
Q2 		$1.25M Buy
20,527
+16,102
+364% +$1.02M 0.01% 157
2021
Q1 		$310K Buy
4,425
+4,330
+4,558% +$309K ﹤0.01% 251
2020
Q4 		$6K Buy
+95
New +$5.56K ﹤0.01% 676
2017
Q4 		– Sell
-19
Closed – – 840
2017
Q3 		$0 Buy
+19
New +$765 ﹤0.01% 876

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's PCRX Position: Q3 2025 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 400 shares — an estimated $9.56K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in PCRX in Q3 2017 and held it in 20 quarters. The position peaked at $3.35M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 400 Pacira BioSciences shares in Q3 2025, an estimated $9.56K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Pacira BioSciences in Q3 2017 and held it in 20 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Pacira BioSciences position peaked at $3.35M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.